AVANOS MEDICAL INC (AVNS) Stock Fundamental Analysis

NYSE:AVNS • US05350V1061

15.2 USD
+0.29 (+1.95%)
At close: Feb 18, 2026
15.2 USD
0 (0%)
After Hours: 2/18/2026, 8:15:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

AVNS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AVNS get a neutral evaluation. Nothing too spectacular is happening here. AVNS is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • AVNS had positive earnings in the past year.
  • AVNS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: AVNS reported negative net income in multiple years.
  • Of the past 5 years AVNS 4 years had a positive operating cash flow.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -43.92%, AVNS is doing worse than 64.86% of the companies in the same industry.
  • AVNS has a Return On Equity (-60.27%) which is in line with its industry peers.
  • AVNS has a better Return On Invested Capital (2.68%) than 68.65% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AVNS is significantly below the industry average of 8.75%.
  • The last Return On Invested Capital (2.68%) for AVNS is above the 3 year average (2.58%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -43.92%
ROE -60.27%
ROIC 2.68%
ROA(3y)-11.6%
ROA(5y)-7.22%
ROE(3y)-16.14%
ROE(5y)-10.03%
ROIC(3y)2.58%
ROIC(5y)N/A
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

  • Looking at the Operating Margin, with a value of 4.46%, AVNS is in the better half of the industry, outperforming 68.65% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AVNS has grown nicely.
  • AVNS's Gross Margin of 52.28% is in line compared to the rest of the industry. AVNS outperforms 48.65% of its industry peers.
  • In the last couple of years the Gross Margin of AVNS has remained more or less at the same level.
Industry RankSector Rank
OM 4.46%
PM (TTM) N/A
GM 52.28%
OM growth 3Y42.57%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5Y-0.78%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AVNS is destroying value.
  • AVNS has less shares outstanding than it did 1 year ago.
  • AVNS has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AVNS has a worse debt to assets ratio.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • AVNS has an Altman-Z score of 1.39. This is a bad value and indicates that AVNS is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.39, AVNS perfoms like the industry average, outperforming 56.76% of the companies in the same industry.
  • AVNS has a debt to FCF ratio of 1.38. This is a very positive value and a sign of high solvency as it would only need 1.38 years to pay back of all of its debts.
  • AVNS has a better Debt to FCF ratio (1.38) than 89.19% of its industry peers.
  • AVNS has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • AVNS has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AVNS outperforms 63.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 1.38
Altman-Z 1.39
ROIC/WACC0.27
WACC10.11%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • AVNS has a Current Ratio of 2.38. This indicates that AVNS is financially healthy and has no problem in meeting its short term obligations.
  • AVNS's Current ratio of 2.38 is in line compared to the rest of the industry. AVNS outperforms 45.41% of its industry peers.
  • AVNS has a Quick Ratio of 1.36. This is a normal value and indicates that AVNS is financially healthy and should not expect problems in meeting its short term obligations.
  • AVNS's Quick ratio of 1.36 is on the low side compared to the rest of the industry. AVNS is outperformed by 61.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 1.36
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for AVNS have decreased by -7.76% in the last year.
  • AVNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.32% yearly.
  • AVNS shows a small growth in Revenue. In the last year, the Revenue has grown by 2.70%.
  • Measured over the past years, AVNS shows a decrease in Revenue. The Revenue has been decreasing by -0.28% on average per year.
EPS 1Y (TTM)-7.76%
EPS 3Y3.09%
EPS 5Y3.32%
EPS Q2Q%-38.89%
Revenue 1Y (TTM)2.7%
Revenue growth 3Y-2.61%
Revenue growth 5Y-0.28%
Sales Q2Q%4.34%

3.2 Future

  • Based on estimates for the next years, AVNS will show a small growth in Earnings Per Share. The EPS will grow by 5.00% on average per year.
  • AVNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.56% yearly.
EPS Next Y-27.14%
EPS Next 2Y-12.3%
EPS Next 3Y5%
EPS Next 5YN/A
Revenue Next Year1.39%
Revenue Next 2Y1.77%
Revenue Next 3Y1.56%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 14.21, the valuation of AVNS can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 90.27% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.27, AVNS is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 15.69, AVNS is valued correctly.
  • Based on the Price/Forward Earnings ratio, AVNS is valued cheaper than 88.11% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AVNS to the average of the S&P500 Index (28.16), we can say AVNS is valued slightly cheaper.
Industry RankSector Rank
PE 14.21
Fwd PE 15.69
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • AVNS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AVNS is cheaper than 91.35% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AVNS is valued cheaply inside the industry as 98.38% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.45
EV/EBITDA 10.1
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)4.27
EPS Next 2Y-12.3%
EPS Next 3Y5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AVNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVANOS MEDICAL INC

NYSE:AVNS (2/18/2026, 8:15:11 PM)

After market: 15.2 0 (0%)

15.2

+0.29 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners96.89%
Inst Owner Change32.3%
Ins Owners2.95%
Ins Owner Change-0.82%
Market Cap705.58M
Revenue(TTM)699.90M
Net Income(TTM)-468.90M
Analysts43.33
Price TargetN/A
Short Float %7.65%
Short Ratio6.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.42%
Min EPS beat(2)11.11%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)33.85%
Min EPS beat(4)2.94%
Max EPS beat(4)79.74%
EPS beat(8)4
Avg EPS beat(8)13.31%
EPS beat(12)7
Avg EPS beat(12)15.99%
EPS beat(16)10
Avg EPS beat(16)13.31%
Revenue beat(2)2
Avg Revenue beat(2)4.82%
Min Revenue beat(2)3.67%
Max Revenue beat(2)5.97%
Revenue beat(4)3
Avg Revenue beat(4)2.62%
Min Revenue beat(4)-0.66%
Max Revenue beat(4)5.97%
Revenue beat(8)3
Avg Revenue beat(8)0.51%
Revenue beat(12)3
Avg Revenue beat(12)-1.11%
Revenue beat(16)3
Avg Revenue beat(16)-4.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)13.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.81%
Valuation
Industry RankSector Rank
PE 14.21
Fwd PE 15.69
P/S 1.01
P/FCF 9.45
P/OCF 6.77
P/B 0.91
P/tB 2.7
EV/EBITDA 10.1
EPS(TTM)1.07
EY7.04%
EPS(NY)0.97
Fwd EY6.38%
FCF(TTM)1.61
FCFY10.59%
OCF(TTM)2.24
OCFY14.77%
SpS15.08
BVpS16.76
TBVpS5.64
PEG (NY)N/A
PEG (5Y)4.27
Graham Number20.09
Profitability
Industry RankSector Rank
ROA -43.92%
ROE -60.27%
ROCE 3.39%
ROIC 2.68%
ROICexc 2.9%
ROICexgc 7.4%
OM 4.46%
PM (TTM) N/A
GM 52.28%
FCFM 10.67%
ROA(3y)-11.6%
ROA(5y)-7.22%
ROE(3y)-16.14%
ROE(5y)-10.03%
ROIC(3y)2.58%
ROIC(5y)N/A
ROICexc(3y)2.84%
ROICexc(5y)N/A
ROICexgc(3y)9.32%
ROICexgc(5y)N/A
ROCE(3y)3.26%
ROCE(5y)N/A
ROICexgc growth 3Y51.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y59.93%
ROICexc growth 5YN/A
OM growth 3Y42.57%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5Y-0.78%
F-Score6
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 1.38
Debt/EBITDA 1.3
Cap/Depr 72.84%
Cap/Sales 4.21%
Interest Coverage 250
Cash Conversion 145.33%
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 1.36
Altman-Z 1.39
F-Score6
WACC10.11%
ROIC/WACC0.27
Cap/Depr(3y)39.4%
Cap/Depr(5y)44.02%
Cap/Sales(3y)2.53%
Cap/Sales(5y)2.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.76%
EPS 3Y3.09%
EPS 5Y3.32%
EPS Q2Q%-38.89%
EPS Next Y-27.14%
EPS Next 2Y-12.3%
EPS Next 3Y5%
EPS Next 5YN/A
Revenue 1Y (TTM)2.7%
Revenue growth 3Y-2.61%
Revenue growth 5Y-0.28%
Sales Q2Q%4.34%
Revenue Next Year1.39%
Revenue Next 2Y1.77%
Revenue Next 3Y1.56%
Revenue Next 5YN/A
EBIT growth 1Y-18.96%
EBIT growth 3Y38.85%
EBIT growth 5YN/A
EBIT Next Year51.47%
EBIT Next 3Y22.03%
EBIT Next 5YN/A
FCF growth 1Y104.1%
FCF growth 3Y7.73%
FCF growth 5YN/A
OCF growth 1Y95.13%
OCF growth 3Y4.87%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 6 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


Can you provide the profitability details for AVANOS MEDICAL INC?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for AVNS stock?

The Earnings per Share (EPS) of AVANOS MEDICAL INC (AVNS) is expected to decline by -27.14% in the next year.